OSE Immunotherapeutics’ immuno-oncology platform is comprised of three programs, one of which is currently in clinical status.

OSE Immunotherapeutics is a leader in the research and development of a myeloid checkpoint inhibitor targeting the SIRPα / CD47 receptor pathway, BI 765063 (OSE-172). BI 765063 is being investigated in an ongoing Phase 1 clinical trial in advanced solid tumors under a license and collaboration agreement with Boehringer Ingelheim.

In collaboration with the CRTI (Center for Research in Transplantation and Immunology, Nantes), the Company has characterized CLEC-1 (a C-type lectin receptor) as a novel myeloid immune checkpoint and validated the first monoclonal antibody antagonists of CLEC-1 as an innovative new potential therapeutic in cancer immunotherapy.

The Company has developed a bispecific fusion protein platform (BiCKI^®) built on the key backbone component anti-PD-1 (OSE-279), a novel standard of care treatment in oncology, and paired with innovative immunotherapy targets. The BiCKI^® platform strives to inhibit key immune checkpoints while simultaneously delivering intratumoral cytokines with Treg modulating function and/or increasing exhausted T cell responses.

Moreover, Tedopi^®, antitumor combination of neoepitopes and therapeutic vaccine, has shown positive Step-1 Phase 3 results of its Atalante 1 trial in non-small cell lung cancer with a significant increase to overall survival and good safety profile.